BACKGROUND: Statins are first-line for cholesterol lowering and prevention of atherosclerotic cardiovascular disease (ASCVD), but their use is complicated by side effects and potential for drug-drug interactions. Provider-patient communication is the basis of the recommended shared decision-making, but relatively little is known about this in the context of statin use. METHODS: We surveyed 5014 US adults prescribed a statin for hypercholesterolemia to learn their perspectives on communication with their provider. RESULTS: Ninety-four percent reported currently taking a statin while 6% had stopped. Past users vs current users were more likely to be female, age < 65 years, and to have fewer cardiovascular disease-related comorbidities (hypertension, type 2 diabetes mellitus, and coronary heart disease, respectively). Although 93% of current statin users were taking ≥1 other prescription medications (median of 4), 76% were "not at all"/"not very concerned" about potential drug-drug interactions with their statin, and fewer than one-quarter recalled mention of these from their provider. Ninety-five percent of subjects said it was "extremely"/"somewhat" important that their healthcare provider take "an individualized approach to selecting the right statin," but 73% and 76%, respectively, said their statin choice was made with little or no input from them. Only 25% were told that "some statins might be more likely than others to interact with other medications," and only 18% (and only 20% of past users) were told that "their particular statin might interact with other medications." CONCLUSION: Provider-patient communication regarding statin therapy appears inadequate, by patient recall, and efforts to improve it are warranted.
BACKGROUND: Statins are first-line for cholesterol lowering and prevention of atherosclerotic cardiovascular disease (ASCVD), but their use is complicated by side effects and potential for drug-drug interactions. Provider-patient communication is the basis of the recommended shared decision-making, but relatively little is known about this in the context of statin use. METHODS: We surveyed 5014 US adults prescribed a statin for hypercholesterolemia to learn their perspectives on communication with their provider. RESULTS: Ninety-four percent reported currently taking a statin while 6% had stopped. Past users vs current users were more likely to be female, age < 65 years, and to have fewer cardiovascular disease-related comorbidities (hypertension, type 2 diabetes mellitus, and coronary heart disease, respectively). Although 93% of current statin users were taking ≥1 other prescription medications (median of 4), 76% were "not at all"/"not very concerned" about potential drug-drug interactions with their statin, and fewer than one-quarter recalled mention of these from their provider. Ninety-five percent of subjects said it was "extremely"/"somewhat" important that their healthcare provider take "an individualized approach to selecting the right statin," but 73% and 76%, respectively, said their statin choice was made with little or no input from them. Only 25% were told that "some statins might be more likely than others to interact with other medications," and only 18% (and only 20% of past users) were told that "their particular statin might interact with other medications." CONCLUSION: Provider-patient communication regarding statin therapy appears inadequate, by patient recall, and efforts to improve it are warranted.
Authors: Arja Helin-Salmivaara; Piia T Lavikainen; Maarit J Korhonen; Heli Halava; Jaana E Martikainen; Leena K Saastamoinen; Lauri Virta; Timo Klaukka; Risto Huupponen Journal: Am J Manag Care Date: 2010-02 Impact factor: 2.229
Authors: Dean G Karalis; Robert A Wild; Kevin C Maki; Ray Gaskins; Terry A Jacobson; Craig A Sponseller; Jerome D Cohen Journal: J Clin Lipidol Date: 2016-03-14 Impact factor: 4.766
Authors: Paul S Jellinger; Yehuda Handelsman; Paul D Rosenblit; Zachary T Bloomgarden; Vivian A Fonseca; Alan J Garber; George Grunberger; Chris K Guerin; David S H Bell; Jeffrey I Mechanick; Rachel Pessah-Pollack; Kathleen Wyne; Donald Smith; Eliot A Brinton; Sergio Fazio; Michael Davidson Journal: Endocr Pract Date: 2017-04 Impact factor: 3.443
Authors: Jingzhi Yu; Ann A Wang; Lindsay P Zimmerman; Yu Deng; Thanh-Huyen T Vu; Yacob G Tedla; Nicholas D Soulakis; Faraz S Ahmad; Abel N Kho Journal: J Gen Intern Med Date: 2022-01-08 Impact factor: 6.473
Authors: Su Golder; Davy Weissenbacher; Karen O'Connor; Sean Hennessy; Robert Gross; Graciela Gonzalez Hernandez Journal: Drug Saf Date: 2022-08-07 Impact factor: 5.228
Authors: Sarah T Ahmed; Julia M Akeroyd; Dhruv Mahtta; Richard Street; Jason Slagle; Ann Marie Navar; Neil J Stone; Christie M Ballantyne; Laura A Petersen; Salim S Virani Journal: J Am Heart Assoc Date: 2020-11-10 Impact factor: 5.501